| Publicaties |
van der Waal RIF, Slee PHTJ, Eland IA, Schagen van Leeuwen JH, Timmer T, Schramel FMNH, Goedkoop AY, Veersema S, Los M, de Jong PC. Hypertrichosis lanuginosa acquisita als paraneoplastische manifestatie: minder zeldzaam dan gedacht. Nederlands Tijdschrift voor Dermatologie en Venereologie 2009; 19(1):19-24.
Canton RF, Scholten DE, Marsh G, de Jong PC, van den Berg M. Inhibition of human placental aromatase activity by hydroxylated polybrominated diphenyl ethers (OH-PBDEs). Toxicology & Applied Pharmacology 2008; 227(1):68-75.
van Meeuwen JA, van Son O, Piersma AH, de Jong PC, van den Berg M. Aromatase inhibiting and combined estrogenic effects of parabens and estrogenic effects of other additives in cosmetics. Toxicology & Applied Pharmacology 2008; 230(3):372-382.
van Meeuwen JA, Nijmeijer S, Mutarapat T, Ruchirawat S, de Jong PC, Piersma AH, van den Berg M. Aromatase inhibition by synthetic lactones and flavonoids in human placental microsomes and breast fibroblasts -- A comparative study. Toxicology & Applied Pharmacology 2008; 228(3):269-276.
de Jong P, Braak S, van Heeswijk J, Grutters JC, van Ginneken B, van den Bosch JM, Nossent GD, Prokop M. Development of a CT scoring system for assessing prognosis in pulmonary sarcoidosis. RSNA 2007.
de Jong PC, van Vugt SF. Severe hypocalcemia during treatment with alendronate. 19e Internistendagen Abstractboek (Abstracts submitted to the Annual Meeting of the Netherlands Society of Internal Medicine, Maastricht, the Netherlands) 2007;63.
Slee PHThJ, Luermans JGLM, de Jong PC, van den Brand MWM, Vijverberg PLM. Behandeling van patienten met een gemetastaseerd testiscarcinoom in een groot niet-academisch ziekenhuis: vergelijking met literatuurgegevens. Nederlands Tijdschrift voor Oncologie 2007; 4(8):369-375.
van Meeuwen JA, Korthagen N, de Jong PC, Piersma AH, van den Berg M. (Anti)estrogenic effects of phytochemicals on human primary mammary fibroblasts, MCF-7 cells and their co-culture. Toxicology & Applied Pharmacology 2007; 221(3):372-383.
Luermans JGLM, van de Brand MWM, Slee PHThJ, de Jong PC, Vijverberg PLM. Data on treatment and outcome in patients with germ-cell malignancies in a large general hospital. 18e Internistendagen Abstractboek 2006;71.
Canton RF, Scholten D, Marsh G, de Jong PC, van den Berg M. Hydroxy and methoxy (OH-and CH30-) derivatives of PBDEs are disruptors of in vitro steroidogenic metabolism. Congres Dioxin 2005, 21-26 augustus, Toronto, Canada 2005.
de Jong PC. Oedeem bij de oncologische patient: complicaties van ziekte en chemotherapie. Oedeminus 2005; 8(1):20-21.
de Jong PC. Inleiding namens de maatschap Inwendige Ziekten en de vakgroep Maag- Darm- Leverziekten. In: de Valois JC, Schramel FMNH, Knibbe CAJ, Hoppezak-Kotting WI, editors. Antonius onderzocht / onderzoekt : uitgegeven ter gelegenheid van het 95-jarig bestaan van het St. Antonius Ziekenhuis. [s.l.: s.n.], 2005: 64-65.
Heneweer M, Muusse M, Dingemans M, de Jong PC, van den Berg M, Sanderson JT. Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Toxicological Sciences 2005; 83(2):257-263.
Heneweer M, van den Berg M, de Geest MC, de Jong PC, Bergman A, Sanderson JT. Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in primary culture of human mammary fibroblasts. Toxicology & Applied Pharmacology 2005; 202(1):50-58.
Slee PHThJ, de Jong PC, de Jong RS, Honkoop A, Coenen JL, Rodenburg C, Eelkman Rooda S, Coenen J, Douma J. Combination chemotherapy with docetaxel and gemcitabine in anthracycline pretreated patients with metastatic breast cancer (MBC). Journal of Clinical Oncology 2005; 23(16S):728.
Heneweer M, van den Berg M, de Jong PC, Bergman A, Sanderson JT. Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in H295R cells and in primary culture of human mammary fibroblasts. Society of Toxicology congres, Baltimore, USA, maart 2004 2004.
Heneweer M, Muusse M, de Jong PC, van den Berg M, Sanderson JT. Co-culture of primary human mammary fibroblasts and MCF-7 cells as an in vitro breast cancer model. Aromatase 2004, Edinburgh 6-8 september 2004 2004.
Slee PHThJ, de Jong RS, Honkoop A, Rodenburg CJ, Eelkman Rooda S, Coenen J, de Jong PC, Douma JH. Combination chemotherapy with docetaxel and gemcitabine in anthracycline pretreated patients with metastatic breast cancer (MBC). Journal of Clinical Oncology 2004; 22(14S):792.
van den Berg M, Heneweer M, de Geest MC, de Jong PC, Bergman A, Sanderson JT. Inhibition of aromatase activity by methyl sulfonyl PCB metabolites in primary culture of human mammary fibroblasts. Organohalogen Compounds 2004; 66:3021.
van Duursen MB, Sanderson JT, de Jong PC, Kraaij M, van den Berg M. Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage. Toxicological Sciences 2004; 81(2):316-324.
de Jong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH, Lu Q, Jelovac D, Brodie AM. The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. Journal of Steroid Biochemistry & Molecular Biology 2003; 87(2-3):149-155.
Heneweer M, van den Berg M, de Jong PC, Bergman A, Sanderson JT. Modulation of aromatase activity in primary culture of human mammary fibroblasts. Society of Toxicology Salt Lake City USA 2003;(maart).
Nortier JW, de Jong PC. Steroïden en borstkanker. Nederlands Tijdschrift voor Klinische Chemie 2003; 28(4):189-191.
Pronk WG, Baars JP, de Jong PC, Westermann AM. Some unusual paraneoplastic syndromes. Case 2. Digital ulceration as a paraneoplastic syndrome in ovarian cancer. Journal of Clinical Oncology 2003; 21(13):2620-2622.
Brodie AM, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, de Jong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH. Aromatase and COX-2 expression in human breast cancers. Journal of Steroid Biochemistry & Molecular Biology 2001; 79(1-5):41-47.
de Jong PC, van de Ven J, Nortier JWR, Blankenstein MA, van Bochove A, Slee PHThJ, Donker TH, Blijham GH, Thijssen JHH. Inhibition of intratumoral aromatase activity and estradiol by exemestane in postmenopausal breast cancer patients: results of a double blind randomised study. Proceedings of the American Society of Oncology 20 2001;abstract 130.
de Jong PC, Blankenstein MA, van de Ven J, Nortier JWR, Blijham GH, Thijssen JHH. The importance of local aromatase activity in hormone dependent breast cancer : a review. Breast 2001; 10(2):91-99.
de Jong PC. Intratumoural aromatase and aromatase inhibitors in breast cancer. [s.l.: s.n.], 2001.
Thijssen JHH, van de Ven J, de Jong PC, Blankenstein MA. Aromatase and oestrogen biosynthesis in the breast. 2nd International Symposium of the Portugese Menopause Society: "Menopause: Hormones and Cancer" 2001.
de Jong PC, Lu Q, Blankenstein MA, Brodie A, Nortier JWR, Slee PHThJ, van de Ven J, van Gorp JM, Elbers JR, Blijham GH, Thijssen JH. The relationship between immunohistochemical staining with a monoclonal antibody for aromatase in breast tumors and response to treatment with aromatase inhibitors. Proceedings of the American Society of Oncology 19 2000;abstract 382.
Blankenstein MA, van de Ven J, Maitimu-Smeele I, Donker GH, de Jong PC, Daroszewski J, Szymczak J, Milewicz A, Thijssen JH. Intratumoral levels of estrogens in breast cancer. Journal of Steroid Biochemistry & Molecular Biology 1999; 69(1-6):293-297.
de Jong PC, Blijham GH. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women. Netherlands Journal of Medicine 1999; 55(2):50-58.
de Jong PC, van de Ven J, Nortier JWR, Maitimu-Smeele I, Donker GH, Thuijssen JHH, Slee PHTJ, Blankenstein MA. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third generation aromatase inhibitor vorozole. European Journal of Cancer 1998; 34(suppl 1.2):S5.
de Jong PC, van de Ven J, Nortier HW, Maitimu-Smeele I, Donker TH, Thijssen JH, Slee PH, Blankenstein RA. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole. Cancer Research 1997; 57(11):2109-2111.
van de Ven PJ, de Jong PC, Jansen GH, Blijham GH. Microscopische tumorembolieen bij gemetastaseerd mammacarcinoom. Nederlands Tijdschrift voor Geneeskunde 1997; 141(11):536-540. |